THE DERMSHIELD™️
TECHNOLOGY

HIGH CONCENTRATION, NO IRRITATION

DermShield™ is a revolutionary skincare technology that enables the formulation of active ingredients at breakthrough high concentration levels without causing skin irritation and other side effects.

The Challenge With High- Strength Therapeutic Skincare

Maximizing the potency of therapeutic skincare such as AHA/BHA peels and creams requires high acid concentration and low pH level, which are conditions that can lead to side effects such as itching, stinging, redness, swelling, and discomfort.
That is why other skincare manufacturers reduce the concentration of active ingredients and increase the pH level of their products, resulting in a much less effective treatment.

The Noon Aesthetics™ Solution: Introducing DermShield™

DermShield™ technology enables the use of high concentration levels of active ingredients without the risk of side effects on all skin types, all year round.

How DermShield™ Works

DermShield™ temporarily inhibits the chemical-sensitive receptors in the skin (called Type C Nociceptors) which are responsible for triggering neurogenic inflammation, redness, and irritation of the skin. By inhibiting C Nociceptors innervations in the skin, DermShield™ dramatically reduces the sensation of irritation and stinging, redness, and other symptoms of neurogenic inflammation. This, in turn, allows NOON™ to significantly increase the concentration of therapeutic active ingredients without triggering adverse side effects such as excessive irritation and redness.

The DermShield™’s Mechanism of Action:

  1. Temporary inhibition of type C Nociceptors in the skin.
  2. Reduced alarm signal transmissions to the brain.
  3. Decreased development of neurogenic inflammation, irritation, and redness.
  4. Much more pleasant treatment experience, no side effects, and more dramatic results due to higher concentration of active ingredients.

DermShield™ Clinical Study 

The Efficacy and Safety of a Novel Protective Complex Combined with 50% Glycolic Acid Peel: A Double- Blinded, Split Face, Controlled Study Ofir Artzi MD, Lee Heyman MD, Rafael L. Carasso MD, Joseph N. Mehrabi MSc, JDD, December 2021 

Description #5: A recent clinical study (Dec 2021) published in the Journal of Drags in Dermatology (JDD) demonstrated the efficacy and safety of the DermShield™ technology in a double-blinded, split-face, controlled settings. The study demonstrated a 95% reduction in neurogenic inflammation reaction, redness, and irritation, as well as significantly shorter recovery time, when DermShield™ technology was used. The study concluded that DermShield™ technology is a “highly effective, safe modality in the reduction of erythema, pain, and itching after 50% glycolic acid peeling, and it provides an advantage in the post-healing treatment period”